Trial Profile
A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUX-Head & Neck 4
- Sponsors Boehringer Ingelheim
- 22 Aug 2016 Status changed from recruiting to discontinued.
- 12 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Jun 2014 Planned initiation date changed from 1 Jun 2014 to 1 Jul 2014, as per ClinicalTrials.gov record.